Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)
November 8, 2022 10:33 AM EST
FDA+
Manufacturing

FDA warns Bris­tol My­ers Squibb for im­prop­er­ly in­ves­ti­gat­ing con­t­a­m­i­na­tion at site that makes Abrax­ane

Zachary Brennan

Senior Editor

Fol­low­ing a 10-day in­spec­tion ear­li­er this year, the FDA has sent a warn­ing let­ter with sev­er­al point­ed ques­tions to a Phoenix-based site, which is run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times